Phase I/II Open-Label Monocentric Clinical Trial for Induction of Tolerance With CD34-Enriched Autologous Hematopoietic Stem Cell Transplantation After High-Dose Chemotherapy With Cyclophosphamide and Rabbit-Antithymocyte Globulin for Refractory Autoimmune Diseases
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease-free survival
24 months
No
Renate Arnold, Prof. Dr. med.
Principal Investigator
Charite University, Berlin, Germany
Germany: Paul-Ehrlich-Institut
CT-0198
NCT00742300
January 1998
Name | Location |
---|